BMS, Sanofi Escape Plavix FCA Suit Under Escobar Standard
By Daniel Wilson ( June 27, 2017, 5:47 PM EDT) -- Bristol-Myers Squibb and Sanofi have escaped a whistleblower False Claims Act suit accusing them of prompting Medicaid overbilling through deceptive marketing of the blood thinner Plavix, after a New Jersey federal judge ruled Tuesday that automatic payment requirements made any implied certifications regarding the drug's effectiveness immaterial to payment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.